LErafAON
Alternative Names: LE-AON; LE-rafAON; LErafAON-ETU; Liposomal encapsulated antisense oligonucleotide c-raf-1Latest Information Update: 21 Aug 2019
At a glance
- Originator Georgetown University
- Developer INSYS Therapeutics, Inc
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Antisense RNA inhibitors; Proto oncogene protein c raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 18 Oct 2016 Discontinued - Preclinical for Solid tumours in USA (IV)
- 05 Mar 2009 Preclinical development is ongoing in USA
- 31 Dec 2006 Discontinued - Phase-I for Solid tumours in USA (IV)